Results 1 to 10 of about 2,094 (131)

Extrafine single inhaler triple therapy effectiveness in COPD patients previously treated with multiple-inhaler triple therapy: the TRIWIN study [PDF]

Therapeutic Advances in Respiratory Disease
Background: The extrafine single inhaler triple therapy (efSITT) containing beclomethasone dipropionate/formoterol fumarate/glycopyrronium 87/5/9 μg has proved to be efficacious in patients with chronic obstructive pulmonary disease (COPD) in randomized ...
Paschalis Steiropoulos, Niki Georgatou, George Krommidas, Konstantinos Bartziokas, Aliki Korkontzelou, Panos Katerelos, Petros Efstathopoulos, Dimosthenis Papapetrou, Stavros Theodorakis, Konstantinos Porpodis   +9 more
doaj   +5 more sources

Metabolic effects following initiation of single-inhaler triple therapy in COPD: a prospective observational study [PDF]

Molecular Medicine
Background Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation, airway inflammation, and oxidative stress. Triple inhaled therapy improves lung function and reduces acute exacerbations, yet its underlying systemic effects ...
Noriane A. Sievi, Felix Schmidt, Diego M. Baur, Kai Fricke, Jonas Herth, Dora Serényi, Maurice Roeder, Nicole Mosca, Silvan Vesenbeckh, Silvia Ulrich, Christian F. Clarenbach, Malcolm Kohler   +11 more
doaj   +4 more sources

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD [PDF]

International Journal of COPD, 2021
Jean Bourbeau,1 Mona Bafadhel,2 Neil C Barnes,3,4 Chris Compton,3 Valentina Di Boscio,3 David A Lipson,5,6 Paul W Jones,3,7 Neil Martin,3,8 Gudrun Weiss,3 David MG Halpin9 1Respiratory Epidemiology and Clinical Research Unit, Department of Medicine ...
Bourbeau J, Bafadhel M, Barnes NC, Compton C, Di Boscio V, Lipson DA, Jones PW, Martin N, Weiss G, Halpin DMG   +9 more
doaj   +7 more sources

Clinical Outcomes Following Transition from ICS/LABA to Single-Inhaler Triple Therapy in Patients with Uncontrolled Asthma: A Real-World Cohort Study [PDF]

Medicina
Background and Objectives: A considerable proportion of patients with asthma remain inadequately controlled despite treatment with inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) therapy.
Melis Yağdıran, Kurtuluş Aksu
doaj   +2 more sources

Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials [PDF]

Respiratory Research, 2021
Background In some RCTs comparing triple therapy with dual therapy in COPD, there might be a bias resulting from the use of multiple inhaler devices. This meta-analysis included only RCTs that compared ICS/LABA/LAMA vs.
Huanyu Long, Hongxuan Xu, Jean-Paul Janssens, Yanfei Guo   +3 more
doaj   +5 more sources

Current appraisal of single inhaler triple therapy in COPD

International Journal of COPD, 2018
Brian Lipworth, Chris RuiWen Kuo, Sunny Jabbal Division of Molecular & Clinical Medicine, Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, University of Dundee, Scotland, UK Abstract: A single inhaler containing ...
Lipworth B, Kuo CRW, Jabbal S
doaj   +6 more sources

The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Life, 2022
There are more single inhaler device triple therapy available for COPD patients now. However, the effect of long-term triple therapy fixed dose combination (FDC) on mortality remains unclear.
Chih-Cheng Lai, Chao-Hsien Chen, Kuang-Hung Chen, Cheng-Yi Wang, Tsan-Ming Huang, Ya-Hui Wang, Hao-Chien Wang   +6 more
doaj   +3 more sources

When single-inhaler triple therapy is a preferred option in asthma management? [PDF]

Ann Thorac Med, 2022
Asthma control is the main goal of management. Unfortunately, most asthma patients with moderate–severe asthma remain uncontrolled despite receiving standard treatment of inhaled corticosteroids (ICS) with long-acting β2 agonists (LABA).
Al-Moamary MS, Al-Lehebi R, Idrees MM, Zeitouni MO.   +3 more
europepmc   +4 more sources

Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial. [PDF]

ERJ Open Res, 2022
BackgroundThe IMPACT trial demonstrated superior outcomes following 52 weeks of once-daily single-inhaler treatment with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) (100/62.5/25 μg) compared with once-daily FF/VI (100/25 μg) or UMEC/VI (62.5/25 μg).
Martin A, Shah D, Ndirangu K, Anley GA, Okorogheye G, Schroeder M, Risebrough N, Ismaila AS.   +7 more
europepmc   +5 more sources

Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. [PDF]

Allergy, 2022
AbstractA significant number of patients with asthma remain uncontrolled despite treatment with inhaled corticosteroids (ICS) and long‐acting β2 adrenergic bronchodilators (LABA). The addition of long‐acting antimuscarinic agents (LAMA) can improve the management of asthma in these patients.
Agusti A, Fabbri L, Lahousse L, Singh D, Papi A.   +4 more
europepmc   +4 more sources